Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2a study of BMS-986517 alone or with BNT327 in advanced solid tumors
2025-522203-23-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of BMS-986517 and pumitamig in Nonhematologic neoplasms, bronchial carcinoma, head and neck cancer (HNC) and 1 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose-limiting toxicities and Overall safety and tolerability. Planned start Dec 2025; status: authorised.
02
Drugs
BMS-986517pumitamig
03
Conditions
Nonhematologic neoplasmsbronchial carcinomahead and neck cancer (HNC)breast cancer
Beyond the preview
Go deeper on 2025-522203-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522203-23-00.